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ABSTRACT Activation of Rap1 small GTPases stabilizes cell–cell junctions, and this activity 
requires Krev Interaction Trapped gene 1 (KRIT1). Loss of KRIT1 disrupts cardiovascular de-
velopment and causes autosomal dominant familial cerebral cavernous malformations. Here 
we report that native KRIT1 protein binds the effector loop of Rap1A but not H-Ras in a GTP-
dependent manner, establishing that it is an authentic Rap1-specific effector. By modeling the 
KRIT1–Rap1 interface we designed a well-folded KRIT1 mutant that exhibited a ∼40-fold-re-
duced affinity for Rap1A and maintained other KRIT1-binding functions. Direct binding of 
KRIT1 to Rap1 stabilized endothelial cell–cell junctions in vitro and was required for cardio-
vascular development in vivo. Mechanistically, Rap1 binding released KRIT1 from microtu-
bules, enabling it to locate to cell–cell junctions, where it suppressed Rho kinase signaling and 
stabilized the junctions. These studies establish that the direct physical interaction of Rap1 
with KRIT1 enables the translocation of microtubule-sequestered KRIT1 to junctions, thereby 
supporting junctional integrity and cardiovascular development.
INTRODUCTION
Rap1 small GTPase regulates both cell–cell and cell–matrix adhe-
sions and numerous other biological functions (Bos, 2005). As is true 
of other Ras-family GTPases, Rap1 cycles between GTP-bound and 
GDP-bound forms. In the GTP-bound form, Rap1 binds to down-
stream effectors, and these effectors are responsible for its biologi-
cal activities. Many Rap1 effectors are shared with other Ras-family 
small GTPases; however, the effects of Rap1 on cell adhesion ap-
pear distinct from those of other Ras-family members (Kinbara et al., 
2003; Bos, 2005). Hence there is a continuing effort to identify Rap1-
specific effectors that regulate adhesion.
Krev Interaction Trapped gene 1 (KRIT1) was identified as a Rap1-
binding protein in a yeast two-hybrid screen; however, the GTP de-
pendence of the interaction was not evaluated (Serebriiskii et al., 
1997). KRIT1 protein is the product of the KRIT1 gene (Laberge-le 
Couteulx et al., 1999; Sahoo et al., 1999). Loss-of-function mutations 
in this gene are responsible for ∼40% of cases of human autosomal 
dominant familial cerebral cavernous malformations (CCMs). Fur-
thermore, KRIT1 is required for normal blood vessel and heart de-
velopment in vertebrates, since mouse homozygous null mutations 
of the Krit1 gene are embryonic lethal due to vascular defects 
(Whitehead et al., 2004), and zebrafish embryos lacking krit1 have 
dilated hearts (Mably et al., 2006). KRIT1 has four ankyrin repeats 
and a C-terminal band 4.1/ezrin/radixin/moesin (FERM) domain 
(Serebriiskii et al., 1997; Sahoo et al., 2001). KRIT1 FERM domain 
binds to heart of glass (HEG1; Kleaveland et al., 2009), a transmem-
brane protein that is genetically linked to KRIT1 (Mably et al., 2006). 
The N-terminus of KRIT1 contains three NPxY(F) motifs, certain of 
which bind to the phosphotyrosine-binding domain protein ICAP1α 
(Zawistowski et al., 2002) or CCM2 (Zawistowski et al., 2005). As 
noted, Rap1A binds to a fragment of KRIT1; both Rap1 and KRIT1 
are regulators of endothelial junctional integrity (Cullere et al., 2005; 
Fukuhara et al., 2005; Kooistra et al., 2005; Wittchen et al., 2005; 
Glading et al., 2007). Thus it is possible that Rap1 binding to KRIT1 
might be responsible for stabilization of those junctions.
In the present study, we found that KRIT1 is an authentic Rap1-
specific effector that binds strongly to the effector loop of active 
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Thus, on the basis of involvement of the Rap1A switch 1 region, GTP 
dependence of binding, and the binding of native full-length KRIT1 
to Rap1A but not H-Ras, we conclude that KRIT1 is an authentic 
Rap1-specific effector.
Mapping the Rap1-binding interface in KRIT1
To analyze the functional importance of Rap1 binding to KRIT1, 
we mapped the KRIT1 region that binds to Rap1. Affinity chroma-
tography showed that the KRIT1 FERM domain binds to Rap1A 
(Figure 1C), in agreement with a previous yeast two-hybrid analysis 
(Serebriiskii et al., 1997). As with the interaction of full-length KRIT1, 
the binding of the FERM domain (F123) to Rap1A was GTP depen-
dent (Figure 1B). Domain analyses (http://smart.embl-heidelberg 
.de/, http://scansite.mit.edu/motifscan_seq.phtml) suggested a po-
tential Ras association domain in the predicted F1 subregion of the 
KRIT1 FERM domain. The importance of this region was confirmed 
by the failure of Rap1A to bind to the F23 fragment of KRIT1, which 
Rap1A [Rap1A(G12V)] but not to an inactive 
Rap1A(S17N) or to an active variant of H-
Ras. We modeled the binding interface be-
tween Rap1A and KRIT1 to create a struc-
ture-based point mutant (R452E) with 
markedly reduced affinity for Rap1. 
KRIT1(R452E) failed to support endothelial 
cell–cell junction stabilization in vitro or car-
diovascular development in Danio rerio. 
KRIT1(R452E) did not localize to cell–cell 
junctions because it was sequestered on mi-
crotubules; however, it bound to both HEG1 
and CCM2. Thus Rap1 binding to the F1 
subdomain of the KRT1 FERM domain frees 
KRIT1 from microtubules, enabling KRIT1 to 
localize to cell–cell junctions and to stabilize 
those junctions.
RESULTS
KRIT1 is an authentic Rap1-specific 
effector
A fragment of KRIT1 was identified as a 
binding partner for Rap1 small GTPase in a 
yeast two-hybrid screen (Serebriiskii et al., 
1997), and that analysis suggested signifi-
cantly less interaction between this protein 
and H-Ras, a closely related small GTPase. 
However, others have failed to see an inter-
action with full-length KRIT1 (Zhang et al., 
2001; Francalanci et al., 2009). To test 
whether KRIT1 is indeed a Rap1-specific ef-
fector, we examined the interaction of re-
combinant human full-length KRIT1 with 
these small GTPases by affinity chromatog-
raphy. Rap1A, but not H-Ras, bound strongly 
to KRIT1 (Figure 1A), whereas both small 
GTPases bound equally well to RalGDS, a 
known common effector (Spaargaren and 
Bischoff, 1994). To assess the GTP depen-
dence of this interaction, similar affinity 
chromatography was performed with either 
constitutively GTP-bound Rap1A (G12V) or 
dominant-negative Rap1A (S17N). Only the 
active Rap1 bound to KRIT1 (Figure 1A). 
Thus full-length native KRIT1 is both Rap1 
specific and GTP dependent in its interactions with the Ras subfam-
ily of small GTPases, consistent with function as a Rap1-specific 
effector.
A common region of Ras GTPases serves as a major binding site 
for most effectors, leading us to examine the role of this region in 
interaction with KRIT1. The crystal structure of Rap1A/c-Raf Ras-
binding domain (RBD) complex (Nassar et al., 1995) reveals that the 
major interaction is mediated by the β2 strand of Rap1A and the β2 
strand and the preceding loop from the c-Raf RBD. The Rap1A β2 
strand is within the so-called switch 1 region containing five amino 
acids (E37, D38, S39, Y40, and R41). To test whether KRIT1–Rap1 
interaction involves the Rap1 switch 1 region, we made alanine mu-
tations at each of those five residues on the constitutively active 
Rap1A (G12V) background and expressed each of them in HEK293 
cells to assess their binding affinities to the KRIT1 FERM domain. 
Two mutants, Rap1A (G12V, E37A) and Rap1A (G12V, D38A), 
showed reduced binding to the KRIT1 FERM domain (Figure 1B). 
FIGuRE 1: KRIT1 is a Rap1-specific effector protein, and its interaction with Rap1 requires the 
F1 subregion of the FERM domain and the switch I domain of Rap1. (A) Recombinant bead-
bound GST-Rap1A, GST-H-Ras, and GST were used to isolate recombinant KRIT1 and RalGDS 
from cell lysates. KRIT1 binds to Rap1A but not H-Ras or GST, whereas RalGDS binds to both 
Rap and Ras proteins (left). KRIT1 preferentially binds active Rap1A (GST-Rap1V12) and does not 
bind to an inactive Rap1 variant (GST-Rap1N17) or to GST only (right). GST blot is shown as 
loading control. Blots are representative; n = 3. Blots were cropped, and intervening lanes were 
removed using Adobe Photoshop. (B) KRIT1–Rap1A interaction involves residues within the 
switch 1 domain of Rap1A. Recombinant Rap1A (V12) from HEK293 cell lysate binds to 
GST-F123 (left). Single-alanine mutation on a switch 1 domain residue D38 (Rap1V12A38) does 
not bind to GST-F123 (right). Another switch 1 domain mutant (Rap1V12A37) dramatically 
reduces the binding to GST-F123 (middle). Blots are representative of three experiments. 
(C) KRIT1 binding to Rap1A is GTP dependent. Recombinant Rap1A from cell lysate binds to the 
KRIT1 FERM domain (GST-F123) only in the presence of GTP (10 mM). Binding of Rap1A to 
GST-KRIT1 FERM is lost on deletion of the F1 region, as binding to truncated FERM domain 
protein (GST-F23) is not observed (top). Expression of GST constructs is shown at bottom; blots 
are representative of three experiments. (D) F1 subregion of KRIT1 FERM domain is sufficient 
for Rap1A binding. Top, recombinant Rap1A (V12) binds to GST-F1 (right) but not GST alone 
(left). Bottom, equal loading of both GST fusion proteins as judged by SDS–PAGE and 
Coomassie Blue staining. Blots are representative of three experiments.
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subdomain, the β2 strand and the preceding loop are in close con-
tact with Rap1A, and Arg452 of KRIT1 is proximal to Rap1A Glu-37 
and Asp-38 residues. We had implicated these acidic Rap1A resi-
dues in the capacity of Rap1A to bind to KRIT1 (Figure 1B), lending 
additional credence to the model. KRIT1 Arg-452 corresponded to 
c-Raf Arg-89, a residue critical for Rap1 binding (Nassar et al., 
1995).
On the basis of the homology model described, we created a 
KRIT1(R452E) mutant and tested its interaction with Rap1. Affinity 
chromatography (Figure 2C) revealed that the FERM domain of 
KRIT1(R452E) exhibited a markedly reduced affinity for Rap1A. We 
also quantified the binding affinity by isothermal titration calorime-
try (ITC) (Figure 3, A and B). The KRIT1 FERM domain bound to 
Rap1 with Kd = 1.8 ± 0.25 μM; however, the KRIT1(R452E) FERM 
bound with a ∼37-fold-lower affinity (Kd = 67 ± 18.7 μM; Table 1). It 
is significant that the R452E mutation did not affect the folding of 
the KRIT1 FERM domain, since it exhibited a sharp melting point 
(57.0 ± 0.1°C vs. 55.7 ± 0.1°C for wild-type FERM domain) in differ-
ential scanning calorimetry (Figure 3C). Thus the KRIT1(R452E) mu-
tant remains well folded but binds to Rap1 with dramatically reduced 
affinity.
The KRIT1–Rap1 interaction stabilizes endothelial  
cell–cell junctions
Rap1 acts to stabilize cell–cell junctions through several potential 
effectors (Bos, 2005), and we proposed KRIT1 as one such effector 
(Glading et al., 2007). Having created a folded KRIT1 point mutant 
with markedly impaired Rap1 binding, we used this mutant to test 
the role of KRIT1–Rap1 interaction in the stabilization of endothelial 
cell–cell junctions. Small interfering RNA (siRNA)–mediated deple-
tion of KRIT1 led to disruption of cell junctions as measured by a 
twofold increase in monolayer permeability; cotransfection of KRIT1 
reversed the increased permeability. In sharp contrast, cotransfec-
tion of KRIT1(R452E) failed to reverse the siRNA-induced permea-
bility increase (Figure 4A), even though it was expressed at similar 
abundance to wild-type KRIT1 (Figure 4B).
KRIT1 suppresses the activity of RhoA and its effector, Rho kinase 
(ROCK), thereby stabilizing endothelial cell–cell junctions (Stockton 
et al., 2010). We therefore examined the capacity of KRIT1(R452E) 
to inhibit phosphorylation of myosin light chain (MLC), a major sub-
strate of ROCK. Depletion of KRIT1 led to increased phosphory-
lated MLC (pMLC), an index of ROCK activity (Figure 4C). This in-
creased pMLC was reversed by reconstitution of KRIT1 but not 
KRIT1(R452E). Reconstituted wild-type and mutant KRIT1 proteins 
were equally abundant in all transfections (unpublished data). Thus 
Rap1 binding to KRIT1 stabilizes endothelial cell–cell junctions by 
inhibiting the RhoA/ROCK signaling pathway.
KRIT1 requires Rap1 binding to support cardiovascular 
development
The foregoing experiments established the importance of Rap1 
binding for KRIT1 function in stabilizing endothelial cell–cell junc-
tions in vitro. In addition to its effects regulating vascular permeabil-
ity, KRIT1 is important in vertebrate cardiovascular development. 
Zebrafish embryos lacking krit1 (also known as santa) exhibit a di-
lated heart phenotype (Mably et al., 2006), and zebrafish krit1 Arg-
449 corresponds to human KRIT1 Arg-452. Injection of an antisense 
morpholino oligonucleotide targeting splice donor site at exon 14 
of krit1 (san MO) (Mably et al., 2006) resulted in cardiac dilation in 
greater than 95% of san MO–injected fish at 48 h postfertilization 
(hpf). Authentic dilation was verified by identifying the endocardium 
in the fluorescence images of flk1:EGFP zebrafish (Figure 5A). 
lacks the F1 subregion (Figure 1C). We also expressed the isolated 
F1 subregion and found that F1 alone was sufficient for Rap1A 
binding (Figure 1D). Thus the FERM domain of KRIT1 binds to Rap1 
in a GTP-dependent manner, and the F1 subregion mediates this 
interaction.
Having mapped the Rap1 binding site to the F1 subdomain, we 
built a homology model of the KRIT1 FERM domain using the 
moesin FERM domain structure (PDB 1EF1) as a template. In this 
model (Figure 2A), the predicted F1 subdomain (orange) contained 
a five-stranded β sheet interrupted by two α helices and structurally 
resembled the c-Raf RBD (Nassar et al., 1995). The model was sub-
jected to conjugate energy minimization in a water-bound environ-
ment in the presence of Rap1 (Figure 2B). The model had good 
structure-packing quality (Z score of 0.83), indicating that the pre-
dicted structure is compatible with the sequence of the KRIT1 FERM 
domain. The major predicted binding interface between Rap1 (blue) 
and KRIT1 (orange) involved the β2 strand from Rap1 switch 1 do-
main, in agreement with our previous results (Figure 1B). In KRIT1 F1 
FIGuRE 2: KRIT1 FERM domain homologous modeling reveals R452 
residue mediating KRIT1–Rap1 interaction. (A) Homology model of 
KRIT1 FERM domain. Residues 410–736 from KRIT1 were modeled 
using the moesin crystal structure as the template. The modeled 
structure is formed by three subdomains that correspond to the F1 
(orange), F2, and F3 (both in green) subregions of the FERM fold. F1 
subregion structurally resembles the c-Raf RBD in a complex with 
Rap1. An arginine residue (R-452), whose corresponding residue in 
c-Raf (R-89) mediates the c-Raf–Rap1 binding, is also conserved in the 
KRIT1 F1 subregion. (B) A closer look at the modeled binding 
interface between KRIT1 F1 subregion (orange) and Rap1 (blue). The 
R452 residue in KRIT1 and switch 1 domain residues in Rap1 are 
shown in black. (C) The R452 residue is crucial for KRIT1–Rap1 
binding. GST-F123 WT pulls down recombinant Rap1V12 from 
HEK293 cell lysate (second lane). The GST-F123(R452E) mutant form, 
which changes a basic residue to an acidic residue, does not bind to 
Rap1V12 (left lane). Bottom, the equal loading of both GST fusion 
proteins as judged by SDS–PAGE and Coomassie Blue staining. Blots 
are representative of five experiments.
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contained N-terminal hemagglutinin (HA) 
tag, and similar protein expression levels 
were confirmed by immunofluorescence mi-
croscopy (Figure 5C). In addition, both wild-
type and mutant proteins were well ex-
pressed in HEK293 cells (Supplemental 
Figure S3). Thus the direct interaction be-
tween Rap1 and KRIT1 is required for KRIT1 
function in cardiovascular development.
Mechanisms of Rap1 regulation 
of KRIT1
The foregoing experiments established that 
Rap1 interaction with KRIT1 is required for 
KRIT1 function. In endothelial cells, KRIT1 
shows three different subcellular localiza-
tions: endothelial cell–cell junctions, cyto-
plasm, and nucleus (Glading et al., 2007). In 
dermal microvascular endothelial cells, 
KRIT1(R452E) and KRIT1(R452E) FERM do-
main failed to localize to cell–cell junctions; 
however, both were present in the cyto-
plasm and the nucleus (Figure 6). β-Catenin 
staining was used as a bona fide endothelial 
cell–cell junction marker. Our results reveal 
that KRIT1 localization to cell–cell junctions 
is controlled by direct binding of the FERM 
domain to Rap1.
KRIT1 has several binding partners that 
regulate its subcellular localization, includ-
ing CCM2 (OSM) (Zawistowski et al., 2005; 
Stockton et al., 2010) and heart of glass 
(HEG1) (Kleaveland et al., 2009). The HEG1 
cytoplasmic domain bound KRIT1(R452E) to 
the same extent as wild-type KRIT1 (Figure 
7A). Similarly, KRIT1(R452E) interacted with 
CCM2 (Figure 7B). Furthermore, the KRIT1 
FERM domain lacks the CCM2-binding site 
(Zhang et al., 2007) and is sufficient to target 
KRIT1 to cell–cell junctions (Glading et al., 
2007). The isolated KRIT1(R452E) mutation 
failed to target KRIT1 to cell–cell junctions, 
thus establishing that Rap1 binding is re-
quired to physically target the KRIT1 FERM 
domain to cell–cell junctions without influ-
encing other known binding partners.
KRIT1 associates with microtubules, and 
transfection of activated Rap1 can reduce 
this association (Gunel et al., 2002; Beraud-Dufour et al., 2007). To 
directly test the importance of KRIT1–Rap1 physical interaction in 
limiting KRIT1 association with microtubules, we expressed green 
fluorescent protein (GFP)–fused KRIT1 or KRIT1(R452E) and exam-
ined interaction with microtubules. The Rap1-binding–deficient mu-
tant KRIT1(R452E) exhibited an approximately eightfold increase in 
association with microtubules compared with the wild-type protein 
(Figure 8, A and B). When the microtubules were depolymerized by 
nocodazole treatment, neither KRIT1 nor KRIT1(R452E) was sedi-
mented (Supplemental Figure S2). Thus the physical association be-
tween KRIT1 and microtubules is inhibited by the direct KRIT1–Rap1 
interaction.
To learn whether the association between KRIT1 and microtu-
bules limits its membrane localization and thus targeting to 
Coinjection of wild-type krit1 cRNA together with san MO resulted 
in less than 5% of fish with dilated hearts (Figure 5B). In sharp con-
trast, 60% of the san MO + krit1(R449E) cRNA–injected fish exhib-
ited dilated hearts. Both wild-type and R449E zebrafish krit1 cRNAs 
n Kd (μM)
ΔHº  
(kcal/mol)
ΔGº  
(kcal/mol)
TΔSº  
(kcal/mol)
Wild type 1.0 1.8 ± 0.25 −9.5 −7.9 −1.6
R452E 1.0 67 ± 18.7 −7.9 −5.7 −2.2
Kd = 1/Ka; ΔGº = –RT ln Ka ; ΔG = ΔH – TΔS.
TABLE 1: Thermodynamic parameters for binding of KRIT1 FERM 
domain, wild type and R452E mutant, to Rap1B bound to GMP-PNP.
FIGuRE 3: Calorimetric characterization of KRIT1 FERM-domain binding to Rap1B bound to 
GMP-PNP, a GTP analogue. (A) Calorimetric titration of 400 μM Rap1B, out of the syringe, into 
45 μM wild-type KRIT1 FERM domain in the sample cell. (B) Titration of 1.2 mM Rap1B into 
45 μM KRIT1(R452E) FERM domain mutant protein. (C) KRIT1(R452E) FERM mutant does not 
disrupt protein folding. Differential scanning calorimetry results of wild-type and R452E FERM 
proteins both exhibit similar narrowly defined melting points, indicating that they are well 
folded.
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tions in endothelial (Glading et al., 2007) 
and epithelial (Glading and Ginsberg, 2010) 
cells. Here we report that KRIT1 is an au-
thentic Rap1-specific effector, in that native 
KRIT1 binds to the switch 1 region of Rap1A 
in a GTP-dependent manner. By modeling 
the KRIT1–Rap1 interface, we developed a 
point mutant of KRIT1 that remains folded 
and interacts with other KRIT1-binding part-
ners but exhibits an ∼40-fold-reduced affin-
ity for Rap1A. By use of this mutant, we 
prove that the KRIT1–Rap1 interaction stabi-
lizes endothelial cell–cell junctions in vitro 
and is required for cardiovascular develop-
ment in vivo. We report that Rap1 binding 
enables KRIT1 function by freeing KRIT1 
from the microtubule cytoskeleton, enabling 
targeting of KRIT1 to cell–cell junctions. Our 
data establish that direct physical interac-
tion of Rap1 and its effector KRIT1 is re-
quired for KRIT1 junctional localization and 
function in endothelial cells and in cardio-
vascular development.
KRIT1 is an authentic Rap1-specific ef-
fector based on four lines of evidence. First, 
full-length KRIT1 protein binds to activated 
Rap1A but not activated H-Ras, indicating 
that KRIT1 specifically binds Rap1 among 
the Ras family of small GTPases. Second, 
full-length KRIT1 and the KRIT1 FERM do-
main bind to GTP-bound Rap1A (V12) but 
not the nucleotide-free form of Rap1A 
(N17), indicating that KRIT1 binds to Rap1 in 
a GTP-dependent manner. Third, point mu-
tations on two residues of the Rap1A switch 
1 region (Glu37 and Asp38) disrupt KRIT1 
binding, indicating that KRIT1 interacts with 
the Rap1A effector–binding domain, which 
is a hallmark of small GTPase–effector inter-
actions (Herrmann and Nassar, 1996). Fourth, the F1 domain of 
KRIT1 resembles a Ras-binding domain, and we show that it inter-
acts with Rap1 in a manner analogous to the Rap1–cRaf interaction. 
Most important, mutation of the Rap1-binding site in KRIT1 blocks 
KRIT1 function, establishing the biological relevance of the direct 
KRIT1–Rap1 interaction. It is particularly notable that among the 
many Rap1-binding proteins known, KRIT1 appears to be unusual in 
its tight binding to Rap1 but not to Ras (Raaijmakers and Bos, 2009). 
Within cells, many Ras-like GTPases may be active. The remarkable 
Rap1 specificity and affinity of KRIT1 suggest that at modest levels 
of Rap1 activation, KRIT1 will be preferentially engaged rather than 
other effectors such as RIAM or afadin. This preferential engage-
ment provides a plausible explanation for the capacity of KRIT1, a 
relatively trace protein (Glading and Ginsberg, 2010), to play a criti-
cal role in the preservation of cell–cell junctions (Glading et al., 
2007).
KRIT1–Rap1 physical interaction is important for KRIT1 func-
tion both in vitro and in vivo because 1) KRIT1 (R452E) mutant did 
not reduce endothelial monolayer permeability and MLC phos-
phorylation in endothelial cells, and 2) zebrafish KRIT1(R449E) 
mutant did not support cardiovascular development. Both CCM2 
and HEG1 bind to KRIT1, and their interactions are important for 
KRIT1 function (Zawistowski et al., 2005; Kleaveland et al., 2009; 
endothelial cell–cell junctions, we expressed either GFP-fused KRIT1 
or KRIT1(R452E) in dermal microvascular endothelial cells. Wild-
type KRIT1 but not the KRIT1(R452E) mutant localized to the plasma 
membrane at endothelial junctions. The KRIT1(R452E) mutant was 
absent from the membrane and colocalized with microtubules (Sup-
plemental Figure S1). When the microtubules were depolymerized 
by nocodazole, the KRIT1(R452E) mutant and the KRIT1(R452E) 
FERM mutant localized to the membrane and partially colocalized 
with VE-cadherin (Figure 8C). It is significant that nocodazole treat-
ment is known to activate the RhoA/ROCK pathway, thus causing 
junctional disruption (Verin et al., 2001); hence we could not test 
whether microtubule depolymerization enabled KRIT1(R452E) to re-
verse the effect of KRIT1 silencing on junctional stability. Thus Rap1 
binding displaces KRIT1 from microtubules, enabling it to translo-
cate to the membrane and to cell–cell junctions.
DISCUSSION
Rap1 GTPase promotes cell–matrix adhesion and cell–cell junction 
formation and maintenance. A large number of potential effectors 
have been identified that might mediate these actions (Bos, 2005); 
however, decisive proof that Rap1 interaction with these effectors 
regulates adhesion is lacking. We previously showed that KRIT1, a 
fragment of which binds to activated Rap1A, stabilizes cell–cell junc-
FIGuRE 4: KRIT1–Rap1 binding regulates HuVEC permeability. (A) Knockdown of KRIT1 
expression by KRIT1 siRNA causes an approximately twofold increase in permeability (left). 
Reconstitution of recombinant WT KRIT1 reverses increased permeability (center). Recombinant 
KRIT1(R452E) mutant does not reverse increased permeability (right). Data shown are mean 
increased percentage over control siRNA in permeability ± SEM; n = 3. *p < 0,05 compared with 
control siRNA. (B) A representative blot of KRIT1 depletion and reexpression of recombinant 
proteins. More than 80% knockdown of KRIT1 is observed by immunoprecipitation and blotting. 
Reconstituted wild-type and RE (arginine 452 to glutamic acid) mutant KRIT1 proteins are 
expressed at equivalent levels. (C, D) Knockdown of KRIT1 expression causes an approximately 
threefold increase in pMLC/total MCL ratio (left). Reconstitution of recombinant WT KRIT1 
reverses MLC phosphorylation increase (center). Recombinant KRIT1(R452E) mutant does not 
reverse increased pMLC level (right). Data shown are mean increased percentage over control 
siRNA; n = 2. (D) Immunoblots of pMLC (top) and total MLC (bottom) in HuVECs.
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Stockton et al., 2010). KRIT1(R452E) mutant interacts with both 
HEG1 and CCM2 to a similar extent as wild-type KRIT1 does. This 
indicates that Rap1 binding does not affect KRIT1 interaction with 
CCM2 and HEG1 per se. KRIT1(R452E) mutant colocalizes and 
cosediments with tubulin and does not localize to cell–cell junc-
tions. Depolymerization of microtubules enables KRIT1(R452E) to 
reach the plasma membrane. Thus Rap1 controls KRIT1 localiza-
tion to cell–cell junctions by facilitating the release of KRIT1 from 
microtubules.
In endothelial cells, KRIT1 shows three different subcellular local-
izations: endothelial cell–cell junctions, cytoplasm, and nucleus 
(Glading et al., 2007). Our data indicate that junctional-localized 
KRIT1 is required for its functions in junctional stabilization and in 
development. That said, the potential functions of cytoplasmic or 
nuclear KRIT1 remain open questions. Nevertheless, it is clear from 
the present work that the regulation of the subcellular localization of 
KRIT1 is important in the integrity of cell–cell junctions. In particular, 
Figure 8D illustrates that KRIT1 binds to CCM2 and thereby exits the 
FIGuRE 5: KRIT1–Rap1 interaction is required for normal zebrafish 
cardiovascular development in vivo. (A) Flk1:EGFP transgenic 
krit1-morphant (san MO) embryo showed enlarged heart phenotype. 
Coinjecting the cRNA encoding HA-tagged wild-type (WT) zebrafish 
krit1 protein reduced the heart size of injected fish, whereas fish 
coinjected with cRNA encoding HA-tagged Krit1(R449E) (RE, 
homologous to human R452E mutant) still exhibited a dilated heart 
phenotype. Dilated heart phenotype was scored by cardiac dilation in 
living fish in combination with a slower heart rate. Authentic dilation 
was verified by identifying the endocardium in the fluorescence 
images, which is indicated by the dotted lines. All microscopic images 
were taken at 48 hpf. Scale bars, 500 μm. (B) Bar graphs showing 
effects of Krit1 RE mutant on zebrafish cardiovascular development. 
Data are expressed as number of embryos with dilated heart 
phenotype divided by total number of embryos used per experiment 
times 100%, mean ± SD. Asterisk indicates p < 0.05 compared to san 
MO + HA-WT cRNA group. Data are from three independent 
experiments. Total number of animals used: 85 in san MO + HA-WT 
group, 120 in san MO + HA-RE group. (C) Lateral views of fixed 
animals at 48 hpf. Right, immunofluorescence images revealing that 
both HA-WT and HA-RE proteins were expressed at similar levels and 
throughout the entire fish. Scale bar, 500 μm.
FIGuRE 6: Rap1 binding determines KRIT1 localization to endothelial 
cell–cell junctions. GFP-fused KRIT1 full-length protein (top) and 
FERM domain (third row from top) colocalize with β-catenin (red) in 
HuVEC cell–cell junctions. GFP-fused KRIT1(R452E) (second row from 
top) and KRIT1(R452E) FERM (bottom) mutants do not localize to 
HuVEC cell–cell junctions, whereas β-catenin (red) localizes to 
junctions. Confocal images are representative; n = 3. Bar, 50 μm.
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MATERIALS AND METHODS
Cell culture and transfection
Human embryonic kidney (HEK) 293 cells were maintained in 
DMEM (Cellgro, Manassas, VA) supplemented with 10% fetal 
bovine serum (FBS) (Sigma-Aldrich, St. Louis, MO), 1% nones-
sential amino acids, 1% l-glutamine, and 1% penicillin and strep-
tomycin (all from Invitrogen, Carlsbad, CA). HEK293 cells were 
transfected using Lipofectamine Plus (Invitrogen) according to 
the manufacturer’s protocol. Human umbilical vein endothelial 
cells (HuVECs; Lonza, Basel, Switzerland) and human dermal mi-
crovascular endothelial cells (HMVECs; ScienCell, San Diego, 
CA) were maintained in EGM-2 supplemented with bullet kit 
(Lonza) or Endothelial Medium (ScienCell) supplemented with 
10% FBS, antibiotic–antimycotic solution, and endothelial cell 
growth substances (Invitrogen). HuVECs and HMVECs were 
transfected either by AMAXA nucleoporation (Lonza) or by using 
FuGENE 6 (Roche, Indianapolis, IN) according to the manufac-
turer’s protocol. U2OS cells were maintained in McCoy’s 5A me-
dium (Cellgro) supplemented with 10% FBS (Sigma-Aldrich), 1% 
nonessential amino acids, 1% l-glutamine, and 1% penicillin and 
streptomycin (all from Invitrogen). U2OS cells were transfected 
using Lipofectamine 2000 (Invitrogen) according to the manufac-
turer’s protocol.
Antibodies, cDNAs, siRNA, and reagents
Monoclonal anti-HA and monoclonal anti–FLAG M2 antibodies 
(both from Sigma-Aldrich) were used for immunoblotting at 1:4000. 
Monoclonal anti-KRIT1 (15B2) and polyclonal anti-KRIT1 (6832) anti-
bodies were previously described (Glading et al., 2007). Mouse 
anti–KRIT1 15B2 antibody was used for immunoprecipitation. Rab-
bit anti–KRIT1 6832 antibody was used for immunoblotting at 
1:1000. Polyclonal anti-pMLC antibody (Cell Signaling, Danvers, 
MA) was used for immunoblotting at 1:1000. Polyclonal anti-GFP 
antibody (Clontech, Mountain View, CA) was used for immunopre-
cipitation. Monoclonal anti-GFP antibody (Clontech) was used for 
immunoblotting at 1:5000. Monoclonal anti–β-tubulin antibody (BD 
Biosciences, San Jose, CA) was used for immunoblotting at 1:2000. 
Monoclonal anti–β-actin antibody (Sigma-Aldrich) was used for im-
munoblotting at 1:4000.
Human KRIT1 siRNA, cDNAs encoding HA- and GFP-tagged 
full-length KRIT1, and KRIT1 FERM domain were previously de-
scribed (Glading et al., 2007). Human KRIT1 R452E mutant was 
generated by site-directed mutagenesis using the QuikChange SD 
mutagenesis kit (Agilent, Santa Clara, CA). The mutant was then 
subcloned into pGEX2TK (GE Healthcare, Piscataway, NJ), 
pcDNA3.1 (Invitrogen), and pEGFP-C1 (Clontech) vectors for ex-
pressing GST-, HA-, and GFP-tagged proteins, respectively. Ze-
brafish krit1 cDNA was a gift from B. Weinstein (National Institutes 
of Health, Bethesda, MD) and subcloned into pcDNA3.1 vector 
(Invitrogen) with an N-terminal HA tag. Zebrafish krit1 (R449E) mu-
tant was generated using the QuikChange SD mutagenesis kit. 
pRK5-CCM2 encoding FLAG-tagged human CCM2 has been pre-
viously described and was the generous gift of Doug Marchuk 
(Duke University, Durham, NC) (Zawistowski et al., 2005). The re-
combinant human HEG1 cytoplasmic tail model protein affinity 
matrix was previously described (Lim et al., 2007; Kleaveland et al., 
2009). Mammalian expression constructs for HA-Rap1A-G12V 
(Rap1V12) and HA-Rap1GAP (RapGAP) have been described (Han 
et al., 2006). HA-Rap1A-G12V E37A, D38A, S39A, Y40A, and R41A 
mutants were generated using the QuikChange SD mutagenesis 
kit. pGEX-H-Ras construct was a gift from D. Broek (University of 
Southern California, Los Angeles, CA).
nucleus (Zawistowski et al., 2005; Francalanci et al., 2009); in the 
cytosol, KRIT1 associates with and is sequestered by microtubules. 
It is possible that KRIT1 is transported along microtubules toward 
cell–cell junctions, thereby contributing to the stabilization of the 
junctions (Verin et al., 2001; Tozer et al., 2005). Activation of Rap1 at 
cell–cell junctions (Hogan et al., 2004; Sakurai et al., 2006) leads to 
its binding to KRIT1, thereby displacing KRIT1 from microtubules 
and increasing its affinity for phosphatidylinositol 4,5-P2 (Beraud-
Dufour et al., 2007). Activated Rap1 may thus facilitate KRIT1 local-
ization to the junctional membrane, where it suppresses RhoA activ-
ity to stabilize the junction. In endothelial cells this pathway functions 
to stabilize vascular development and integrity; however, it is also 
functional in epithelial cells. Indeed, in these cells the KRIT1–Rap1 
pathway stabilizes cell–cell junctions, thereby inhibiting the canoni-
cal Wnt signaling pathway and tumorigenesis triggered by that 
pathway (Glading and Ginsberg, 2010). Thus the present studies 
define a mechanistic basis whereby Rap1 signaling can regulate cell 
junctional integrity in multiple physiological and pathological con-
texts.
FIGuRE 7: Rap1 binding does not affect KRIT1 interactions with 
HEG1 or CCM2. (A) HEG1 cytoplasmic tail model protein binds to 
recombinant KRIT1 WT and R452E mutant proteins from HEK293 cell 
lysates. Integrin αIIb tail model protein does not bind to KRIT1. 
Bottom, the equal loading of tail proteins as judged by SDS–PAGE 
and Coomassie Blue staining. Blots are representative of three 
experiments. (B) Both GFP-fused KRIT1 WT and GFP-fused 
KRIT1(R452E) are associated with CCM2 at equivalent levels as 
assessed by coimmunoprecipitation and immunoblotting. Blots are 
representative of three experiments.
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Homology modeling of KRIT1 FERM 
domain–Rap1 interaction
We used a DeepView Swiss-PdbViewer 
(Swiss Institute of Bioinformatics, Lausanne, 
Switzerland) (Guex and Peitsch, 1997) to 
align the KRIT1 FERM and moesin FERM se-
quences and to build an initial model of 
KRIT1 FERM domain. We then sent the 
alignment to I-TASSER server for protein 
structure and function prediction (Zhang, 
2008, 2009; Roy et al., 2010) and built a re-
vised model of the KRIT1 FERM domain. We 
replaced the c-Raf RBD from the Rap1/c-Raf 
RBD complex crystal structure (PDB 1C1Y) 
with our KRIT1 FERM model and adjusted 
the spatial restraints with Rap1 by using 
Coot (Emsley et al., 2010). This Rap1/KRIT1 
FERM complex model was then completely 
immersed in a water sphere, and the whole 
system was subjected to energy minimiza-
tion by molecular dynamics simulation using 
NAMD program (Phillips et al., 2005). The 
simulation continued for 5 ns until the total 
energy reached the minimum and the RMSD 
was stabilized. The quality of the model was 
assessed by the program QMEAN (Benkert 
et al., 2009). The final model was rendered 
for publication in PyMOL (Schrödinger, New 
York, NY).
In vitro protein interaction assay
Bacterial expression plasmids encoding glu-
tathione S-transferase (GST)–KRIT1 FERM, 
partial KRIT1 FERM domains (F23, F1), 
R452E mutant, GST–RalGDS RBD, or GST 
vector were expressed in BL21 (DE3) (Nova-
gen, Madison, WI), and recombinant pro-
teins were purified on glutathione-Sephar-
ose beads according to manufacturer’s 
instructions (GE Healthcare). HEG1 and αIIb 
intracellular tail model proteins were ex-
pressed and purified as previously described 
(Pfaff et al., 1998). To perform pulldown as-
says using cell lysates, HEK293 cells were 
transfected with indicated cDNAs. At 24 h 
after transfection, cells were lysed in cold 
FIGuRE 8: KRIT1–Rap1 interaction enables KRIT1 release from microtubules. (A) Top, 
KRIT1(R452E) (right two lanes) cosedimented with microtubules eightfold more than KRIT1 wild 
type (left two lanes). Bottom, immunoblotting of β-tubulin to show that the microtubule 
sedimentation is equivalent. P, pellet; S, supernatant; W, whole-cell lysate. (B) Quantification of 
KRIT1 cosedimented with microtubules. KRIT1 in the pellet was normalized to 100%. n = 3. 
(C) When microtubules were depolymerized by nocodazole, GFP-fused KRIT1(R452E) and KRIT1 
FERM(R452E) localized to endothelial cell membranes and colocalized with junction marker 
VE-cadherin (red). Confocal images are 
representative; n = 3. Bar, 50 μm. 
(D) Mechanism of Rap1-mediated KRIT1 
junctional localization. In endothelial cells, 
CCM2 binding enables KRIT1 egress from 
the nucleus. In the cytoplasm, KRIT1 is 
associated with microtubules. Rap1 binds 
KRIT1 and releases KRIT1 from microtubules. 
KRIT1 binds HEG1 to localize to endothelial 
cell–cell junctions, where it associates with 
junctional proteins, including β-catenin and 
VE-cadherin. Endothelial junction–localized 
KRIT1 controls junctional stability by 
suppressing RhoA activation. ECM, 
extracellular matrix.
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In vitro endothelial permeability assay
Human umbilical vein endothelial cells were detached and trans-
fected with indicated DNA and/or siRNA using an Amaxa (Lonza) 
nucleoporation device, then plated onto fibronectin-coated 6-mm 
Transwell filters and grown for 48 h. In some experiments, cells were 
plated into filters and grown to confluence, then transfected using 
FuGENE 6. Upper and lower chamber medium was replaced with 
phenol-free DMEM. Fluorescein isothiocyanate (FITC)–labeled 
40-kDa dextran (2 μg/ml) was added to upper chambers for 2 h, and 
then FITC was quantified in lower chamber medium by fluorimetry. 
Raw fluorescence units were normalized as percentage of control 
treatment.
Immunofluorescence
Human umbilical vein endothelial cells were grown to ∼80% conflu-
ence on fibronectin-coated glass coverslips, then transfected using 
FuGENE 6 reagent and the indicated KRIT1 cDNA. Transfected cells 
were grown for 24 h and then treated for 2 h at 37°C with 5 μM no-
codazole or vehicle, then for 60 min at 37°C with 2 μM taxol or ve-
hicle (Invitrogen). Cells were fixed with 3.7% formaldehyde for 
60 min at 37°C, permeabilized for 7 min with 0.15% Triton X-100, 
and blocked for 1 h with 10% normal goat serum (Invitrogen) in Tris-
buffered saline, pH 7.4, with 0.01% Triton X-100 (TBST). Cells were 
probed with mouse anti–β-catenin antibody (BD Biosciences), anti–
VE-cadherin (Cell Signaling), or mouse antitubulin (Sigma-Aldrich) in 
TBST and with rabbit anti-GFP (Clontech) (all at 1:1000) overnight in 
a humidified chamber. Coverslips were washed with TBST and then 
incubated with indicated Alexa 568–labeled anti–mouse immuno-
globulin (IgG) and anti–rabbit IgG Alexa 488 (Invitrogen) at 1:1000 
overnight at 4°C. Coverslips were washed in TBST and PBS (pH 7.4) 
and then mounted using Prolong Gold (Invitrogen). Imaging was 
performed by a microscope (Leica LR23) with a charge-coupled de-
vice camera (model 2.2.1; Diagnostic Instruments, Sterling Heights, 
MI) or a confocal microscopy system (Leica TCS SP2 AOBS with 
DMRE microscope and HCX PL APO 63×/1.32 oil objective). Images 
were acquired for each experiment using the same gamma setting 
for all samples and processed using Photoshop CS II software 
(Adobe, San Jose, CA). Images shown are representative of results 
from at least three independent experiments.
Zebrafish studies
We maintained and bred antibody wild-type zebrafish and 
Tg(flk1:EGFP) mutant zebrafish. We injected antisense morpholino 
oligonucleotides (Gene-Tools, Eugene, OR) that target splice junc-
tions of krit1 (Mably et al., 2006) or standard nontargeting control 
morpholino oligonucleotides (Gene-Tools) into the yolks of one-cell-
stage embryos at a dose of 1 ng. To rescue the enlarged heart phe-
notype caused by the krit1 morpholino, we coinjected the one-cell-
stage embryos with 1 ng of the krit1 morpholino and 400 pg of 
cRNA encoding HA-tagged krit1 or krit1 (R449E). We used the 
mMessage mMachine T7 ultra kit (Ambion, Austin, TX) to prepare 
cRNAs. We mounted the 48-hpf live embryos laterally in 1.2% aga-
rose and acquired images using a fluorescence imaging system 
(Leica AF6000 with M205 FA stereomicroscope and Leica DFC310 
FX digital color camera).
Paraformaldehyde-fixed (4%) embryos were kept in methanol 
and rehydrated in incubation buffer containing 1× PBS, 0.5% Triton 
X-100, 5% bovine serum albumin, and 2% goat serum. The pri-
mary antibody, rabbit anti-HA tag (Clontech), was used at 1:200 
dilution. The secondary antibody, goat anti–rabbit IgG (H+L) Alexa 
Fluor 488 (Invitrogen), was used at 1:500 dilution. Stained embryos 
were mounted in 50% glycerol images acquired as described 
lysis buffer (50 mM Tris-HCl, pH 7.4, 150 mM NaCl, 0.5% NP-40, and 
5 mM MgCl2) plus protease and phosphatase inhibitor cocktails 
(Roche). A total of 10 μg of immobilized bead-bound proteins was 
added to 350 μg of clarified cell lysates. Reactions were kept at 4°C 
overnight. After washing the beads with lysis buffer, samples were 
fractionated on 4–20% SDS–PAGE gel (Invitrogen). Bound proteins 
were analyzed by immunoblotting or Coomassie Blue staining.
Immunoprecipitation
HEK293 cells were transfected with indicated cDNAs and incubated 
for 24 h. Cells were scraped on ice in lysis buffer plus protease and 
phosphatase inhibitor cocktails (Roche). A total of 2 μg of monoclo-
nal anti-GFP antibody was added to 350 μg of cell lysates and incu-
bated at 4°C overnight. Protein G-Sepharose (Invitrogen) was added 
to the reaction mixture and further incubated for 4 h at 4°C. After 
three washes with lysis buffer, beads were mixed with sample buffer 
and subjected to SDS–PAGE. Immunoprecipitated proteins were 
detected by immunoblotting.
Isothermal titration calorimetry and differential  
scanning calorimetry
Proteins were dialyzed into the ITC buffer (20 mM sodium phos-
phate, pH 6.5, 150 mM NaCl, 3 mM MgCl2, and 0.1 mM guanylimi-
dodiphosphate [GMP-PNP]). The thermodynamic parameters are 
determined using an isothermal titration calorimeter iTC200 (Micro-
Cal, Piscataway, NJ) at 25°C in 20 mM sodium phosphate (pH 6.5), 
150 mM NaCl, 3 mM MgCl2, and 0.1 mM GMP-PNP. For binding, 
0.4 or 1.2 mM Rap1B bound to GMP-PNP was titrated from the sy-
ringe into the sample cell containing 45 μM KRIT1 FERM domain 
wild-type or R452E mutant protein, respectively. Titration was car-
ried out by injecting volumes of 2.5 μl into the sample cell, where 
the time between injections was 2 min. Further data evaluation was 
done using the MicroCal Origin program.
Differential scanning calorimetry experiments were performed at 
a scanning rate of 1 K/min under 3.0 atm of pressure using N-DSC II 
differential scanning calorimeter (Calorimetry Sciences Corp, Provo, 
UT). Differential scanning calorimetry samples contained phosphate-
buffered saline (PBS) (pH 7.4) and 0.8 mg/ml KRIT1 F123 or 
KRIT1F123(R452E).
Protein expression and purification for ITC and differential 
scanning calorimetry
The cDNA encoding human KRIT1 residues 417–736 was synthe-
sized by PCR using a human KRIT1 cDNA as template and cloned 
into the expression vector pLEICS-07 (Protex, Leicester, United 
Kingdom). Constructs were expressed in Escherichia coli BL21 Star 
(DE3) (Invitrogen) cultured in LB media. Recombinant His-tagged 
polypeptides were purified by nickel-affinity chromatography fol-
lowing standard procedures. The His tag was removed by cleav-
age with AcTEV protease (Invitrogen), and the protein was further 
purified by cation-exchange chromatography. The protein concen-
tration was assessed using the A280 extinction coefficient of 
45,090 M−1 before dialysis into buffers. Human Rap1 isoform 
Rap1B (residues 1–167) was cloned into pTAC vector and ex-
pressed in the E. coli strain CK600K (Tucker et al., 1986). Cultures 
were grown at 37°C to A600 of 0.8, when they were induced with 
200 μM IPTG and then cultured at 18°C overnight. Rap1B protein 
was purified by ion exchange, followed by Superdex-75 gel filtra-
tion. Nucleotide exchange was achieved as previously described 
(Gorzalczany et al., 2000), and the final sample was dialyzed into 
ITC buffer. The protein concentration was assessed using the CB 
protein assay (EMD, San Diego, CA).
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earlier. Images were acquired for each experiment using the same 
gamma setting for all examples and processed using Photoshop 
CS II software.
Microtubule sedimentation assay
U2OS cells were transfected with plasmids and treated with either 
vehicle or nocodazole as indicated. The microtubule fraction was 
prepared using a cytoskeleton isolation and assay kit (Cytoskeleton, 
Denver, CO). After centrifugation, the pellets were redissolved in 
cold water on ice for 1 h. To assess GFP-KRIT1 cosedimentation, 
polyclonal anti-GFP antibody (Clontech) was used for immunopre-
cipitation at 4°C overnight. Protein G-Sepharose was added to the 
reaction mixture and further incubated for 4 h at 4°C. After three 
washings with lysis buffer, beads were mixed with sample buffer and 
subjected to SDS–PAGE. Proteins were detected by immunoblot-
ting with monoclonal anti-GFP antibody. The presence of tubulin 
was assessed by immunoblotting with monoclonal anti–β-tubulin 
antibody (BD Biosciences).
Statistics
We calculated p values by using an unpaired two-tailed Student’s t 
test.
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